Scholarlink

<p>Thrombosis is a major complication of myeloproliferative neoplasms (MPNs) and a leading contributor to morbidity and mortality, yet risk prediction data from the Middle East remain scarce, and the prevalence of silent asymptomatic thrombosis has not been well characterized. We conducted a two-center retrospective-prospective cohort study of 83 patients with Philadelphia chromosome-negative MPNs at King Faisal Specialist Hospital and Research Centre (KFSHRC), Jeddah (<i>n</i> = 69) and Medina (<i>n</i> = 14), Saudi Arabia (2015–2025), using 2022 WHO classification criteria. Across the full cohort, thrombosis occurred in 24 patients (28.9%), predominantly in the splanchnic/abdominal venous system (29.2%). Separately, as a prospective screening component, 45 consenting patients without previously known thrombosis underwent single-visit, comprehensive Doppler ultrasonography of the upper limbs, lower limbs, and abdominal vasculature to detect silent thrombosis. Thrombosis rates were virtually identical across both branches (Jeddah 29.0%, Medina 28.6%, <i>p</i> = 1.000). Splenomegaly was significantly more prevalent in thrombotic patients (70.8% [95% CI 50.8–85.1%] vs. 42.4% [95% CI 30.6–55.1%], <i>p</i> = 0.035). Baseline diagnostic platelet counts were paradoxically lower in the thrombosis group (median 393 vs. 682 × 10⁹/L, <i>p</i> = 0.020), driven by splenic sequestration - patients with splenomegaly had markedly lower baseline platelets than those without (412.5 vs. 800.0 × 10⁹/L, <i>p</i> = 0.005). A novel 2-variable composite score (splenomegaly + baseline PLT &lt; 500 × 10⁹/L) produced a significant thrombosis gradient of 12.9, 33.3, and 45.5% across low, intermediate, and high-risk tiers (<i>p</i> = 0.029; AUC 0.677 [95% CI 0.572–0.800]; bootstrap-corrected AUC 0.670). Established risk scores (r-IPSET-T, MIPSS-PV) demonstrated exploratory risk stratification. Systematic Prospective Doppler screening detected no new silent thrombosis (0%; 95% CI 0.0–7.9%), though larger studies are needed to definitively exclude low rates of silent thrombosis.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

A composite splenomegaly and platelet score for thrombosis risk in myeloproliferative neoplasms in Saudi Arabia

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年8月3日

查看全文
  • Noha Eisa,
  • Nouran Alhashimi,
  • Mohammed Almakadi,
  • Abdulaziz Khiyami,
  • Dalal Aldhafeeri,
  • Badr Aljoaid,
  • Ali Alahmadi,
  • Rania Jaha,
  • Naif I. Aljohani

摘要

Thrombosis is a major complication of myeloproliferative neoplasms (MPNs) and a leading contributor to morbidity and mortality, yet risk prediction data from the Middle East remain scarce, and the prevalence of silent asymptomatic thrombosis has not been well characterized. We conducted a two-center retrospective-prospective cohort study of 83 patients with Philadelphia chromosome-negative MPNs at King Faisal Specialist Hospital and Research Centre (KFSHRC), Jeddah (n = 69) and Medina (n = 14), Saudi Arabia (2015–2025), using 2022 WHO classification criteria. Across the full cohort, thrombosis occurred in 24 patients (28.9%), predominantly in the splanchnic/abdominal venous system (29.2%). Separately, as a prospective screening component, 45 consenting patients without previously known thrombosis underwent single-visit, comprehensive Doppler ultrasonography of the upper limbs, lower limbs, and abdominal vasculature to detect silent thrombosis. Thrombosis rates were virtually identical across both branches (Jeddah 29.0%, Medina 28.6%, p = 1.000). Splenomegaly was significantly more prevalent in thrombotic patients (70.8% [95% CI 50.8–85.1%] vs. 42.4% [95% CI 30.6–55.1%], p = 0.035). Baseline diagnostic platelet counts were paradoxically lower in the thrombosis group (median 393 vs. 682 × 10⁹/L, p = 0.020), driven by splenic sequestration - patients with splenomegaly had markedly lower baseline platelets than those without (412.5 vs. 800.0 × 10⁹/L, p = 0.005). A novel 2-variable composite score (splenomegaly + baseline PLT < 500 × 10⁹/L) produced a significant thrombosis gradient of 12.9, 33.3, and 45.5% across low, intermediate, and high-risk tiers (p = 0.029; AUC 0.677 [95% CI 0.572–0.800]; bootstrap-corrected AUC 0.670). Established risk scores (r-IPSET-T, MIPSS-PV) demonstrated exploratory risk stratification. Systematic Prospective Doppler screening detected no new silent thrombosis (0%; 95% CI 0.0–7.9%), though larger studies are needed to definitively exclude low rates of silent thrombosis.